Features
The Pathology of Stargardt Disease and Future Treatment Horizons
Promising approaches to treating this inherited retinal disease are currently being tested in clinical trials.
By Joseph C. Giacalone, MD, PhD, Brittni A. Scruggs, MD, PhD
Best Practices Regarding Choroidal Nevus Follow-up
Differentiation between choroidal nevus and melanoma is essential for effective management and optimal patient outcomes.
By Namita Saraf, Lauren A. Dalvin, MD, Sophie J. Bakri, MD, MBA
Leveraging Social Media to Enhance Your Career
Used correctly, Facebook, Instagram, and other social platforms can be useful tools to educate patients, share expertise, and grow your practice.
By Rehan M. Hussain, MD
Web Exclusives
Clinical Trials Training at Women in Ophthalmology
Experts advise taking advantage of research opportunities and developing relationships with industry partners.
By Christine Nichols Kay, MD, Lisa M. Nijm, MD, JD
Departments
Upfront: A Fond Farewell
Reflecting on 12 years as editor in chief of Retinal Physician.
By Peter K. Kaiser, MD
Coding Q&A: Medicare as a Secondary Payer
In certain cases, health care providers must determine whether Medicare is the primary or secondary payer to ensure correct billing and compliance with regulations.
By Brandy H. Sperry, COMT, COE, CPC, CPMA, Kevin J. Corcoran, COE, FNAO
Clinical Trial Update November/December 2024
Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.
Supported Content
Ultra-Widefield Image of the Month
Simultaneous Rhegmatogenous Retinal Detachment and Choroidal Melanoma: A Rare Occurrence
By Gabriel Velez, MD, PhD, Vinit B. Mahajan, MD, PhD, Prithvi Mruthyunjaya, MD, MHS
Gildeuretinol Shows Positive Visual Signals in SAGA
The oral agent demonstrated a favorable safety profile, and may be effective in combination with other therapies.
By Alex Melamud, MD, Michael A. Singer, MD
Integrating Complement Inhibition Therapy into Clinical Practice
It is crucial to use a multifaceted approach throughout patient conversations about these treatments
By Durga S. Borkar, MD, MMCi
TKIs for AMD Maintenance Therapy: Results from the ODYSSEY Trial
CLS-AX had stable BCVA over 36 weeks and 100% of the patients made it to 12 weeks without redosing of CLS-AX or rescue with aflibercept
By Roger A. Goldberg, MD, MBA, Michael A. Singer, MD